Novo Nordisk A/S

AI Summary

Novo Nordisk develops and sells injectable and oral drugs primarily for diabetes and obesity, operating through two segments: Obesity and Diabetes Care (which includes cardiovascular treatments) and Rare Disease (covering blood disorders and hormone therapies) [Yahoo Finance]. The company also makes insulin delivery devices like smart pens and dose-tracking apps [Yahoo Finance]. Founded in 1923 and headquartered in Denmark, Novo Nordisk employs 67,900 people and sells its products globally across Europe, North America, Asia, and emerging markets [Yahoo Finance].

Novo Nordisk is a Danish pharmaceutical giant that makes diabetes and obesity drugs, most notably Wegovy and Ozempic (both forms of semaglutide) [Yahoo Finance]. The company is riding a massive wave of demand for GLP-1 weight-loss treatments, with recent trial data showing Wegovy works effectively in pill form and treats liver disease affecting one in three people with obesity [Yahoo Finance]. Despite strong financials and positive clinical momentum, the stock trades at a low 10.4x P/E ratio, which some analysts view as undervalued [Yahoo Finance].

Novo Nordisk is financially robust with exceptional margins, strong cash generation, and minimal debt burden [Yahoo Finance].

Recent News

• How New Wegovy Obesity Trial Data At Novo Nordisk (CPSE:NOVO B) Has Changed Its Investment Story

  Yahoo Finance· 2026-05-20

• 3 Deeply Undervalued Stocks You Can Buy for Less Than $100 Right Now

  Yahoo Finance· 2026-05-18

• Novo Nordisk to unveil data showing semaglutide tackles the liver disease crisis affecting about 1 in 3 people living with overweight and obesity worldwide

  Yahoo Finance· 2026-05-19

• Novo Nordisk Expands Parkinson's Bet With AI Partner And Upside Potential

  Simply Wall St· 2026-05-19

• Novo Nordisk A/S - share repurchase programme

  Yahoo Finance· 2026-05-18

• Novo Nordisk Eyes Global Push for Wegovy Pill

  GuruFocus· 2026-05-18